Comparative cardiovascular outcomes in type 2 diabetes patients taking dapagliflozin versus empagliflozin: a nationwide population-based cohort study

Sodium-glucose co-transporter-2 inhibitors displayed cardiovascular benefits in type 2 diabetes mellitus in previous studies; however, there were some heterogeneities regarding respective cardiovascular outcom...

Source: Cardiovascular Diabetology - July 26, 2023 Category: Cardiology Authors: Jaehyun Lim, You-Jung Choi, Bong Sung Kim, Tae-Min Rhee, Hyun-Jung Lee, Kyung-Do Han, Jun-Bean Park, Jin Oh Na, Yong-Jin Kim, Heesun Lee and Hyung-Kwan Kim Tags: Research Source Type: research